Genomic and transcriptional alterations of cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 6, 2014, Pages 380-387

  Ito, Takeshi ^a   Sakurai Yageta, Mika ^a   Goto, Akiteru ^a,b   Pairojkul, Chawalit ^c   Yongvanit, Puangrat ^c   Murakami, Yoshinori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; KRAS; Liver fluke; Opisthorchis viverrini; TP53

Indexed keywords

BETA CATENIN; CAGA PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCURONOSYLTRANSFERASE 1A10; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; P CADHERIN; PROTEIN P53; SMAD4 PROTEIN; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTOR RUNX3; UVOMORULIN;

ANEUPLOIDY; ARID1A GENE; ARTICLE; BAP1 GENE; BILE DUCT CARCINOMA; BURKITT LYMPHOMA; CANCER CELL LINE; CELL ADHESION; CHROMATIN; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 20Q; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHRONIC INFLAMMATION; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS INFECTION; EXOME; FASCIOLIASIS; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GLUCURONOSYLTRANSFERASE 1A10 GENE; GLUCURONOSYLTRANSFERASE 2B11 GENE; HELICOBACTER INFECTION; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; JAPAN; KERATAN SULFATE GAL 6 GENE; KRAS2 GENE; LASER MICROBEAM MICRODISSECTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MUTATION RATE; NASOPHARYNX CANCER; OPISTHORCHIASIS; OPISTHORCHIS VIVERRINI; PATHOGENESIS; SIGNAL TRANSDUCTION; SMAD4 GENE; SULFOTRANSFERASE 1C1 GENE; THAILAND; TRANSCRIPTION REGULATION; TREFOIL FACTOR 3 GENE; UPREGULATION; XENOBIOTIC METABOLISM; ANIMAL; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; GENOMICS; INTRAHEPATIC BILE DUCT; ISOLATION AND PURIFICATION; MALE; OPISTHORCHIS; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GENOMICS; HUMANS; JAPAN; MALE; OPISTHORCHIS; THAILAND; TRANSCRIPTIONAL ACTIVATION;

EID: 84901272705     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.67     Document Type: Article

References (54)

1. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007; 4: 1148-1155.
2. IARC. Infection with liver flukes (Opisthorchis viverrivi, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 121-175.
3. IARC. A review of human carcinogens: Opisthorchis viverrini and Clonorchis sinensis. IARC Monogr Eval Carcinog Risks Hum. 2012; 100B: 341-370.
4. Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012; 12: 289.
5. Kumagai S, Kurumatani N, Arimoto A, Ichihara G,. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med. 2013; 70: 508-510.
6. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, et al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer. 2012; 1: 21-32.
7. Yamamoto M, Ariizumi S,. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today. 2011; 41: 896-902.
8. Kim CM, Koike K, Saito I, Miyamura T, Jay G,. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991; 351: 317-320.
9. Fallot G, Neuveut C, Buendia MA,. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol. 2012; 2: 467-473.
10. Hatakeyama M,. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004; 4: 688-694.
11. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-350.
12. Yoshida M,. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001; 19: 475-496.
13. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006; 44: 1025-1038.
14. Jusakul A, Yongvanit P, Loilome W, Namwat N, Kuver R,. Mechanisms of oxysterol-induced carcinogenesis. Lipids Health Dis. 2011; 10: 44.
15. Murakami Y, Ito T, Goto A, Sakurai-Yageta M,. Towards the control of cholangiocarcinoma by international collaboration between Thailand and Japan. Int Symp Cholangiocarcinoma Tokyo. 2013; 1 (Suppl.): 10-11.
16. Kiguchi K, Carbajal S, Chan K, Beltrán L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001; 61: 6971-6976.
17. Kiguchi K, Kitamura T, Moore T, Rumi M, Chang HC, Treece D, et al. Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis. Cancer Prev Res (Phila). 2010; 3: 940-952.
18. McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford). 2011; 13: 309-319.
19. Miller G, Socci ND, Dhall D, D'Angelica M, DeMatteo RP, Allen PJ,. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res. 2009; 28: 62.
20. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S,. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol. 2009; 40: 834-842.
21. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G,. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001; 130: 22-28.
22. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M,. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 1995; 55: 2756-2760.
23. Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S,. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog. 1992; 6: 266-269.
24. Muenphon K, Limpaiboon T, Jearanaikoon P, Pairojkul C, Sripa B, Bhudhisawasdi V,. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol. 2006; 12: 4143-4148.
25. Limpaiboon T, Tapdara S, Jearanaikoon P, Sripa B, Bhudhisawasdi V,. Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World J Gastroenterol. 2006; 12: 4377-4382.
26. Thanasai J, Limpaiboon T, Jearanaikoon P, Bhudhisawasdi V, Khuntikeo N, Sripa B, et al. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol. 2006; 12: 4338-4344.
27. Dachrut S, Banthaisong S, Sripa M, Paeyao A, Ho C, Lee SA, et al. DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev. 2009; 10: 575-582.
28. Andersen JB, Thorgeirsson SS,. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012; 28: 266-272.
29. O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012; 72: 1557-1567.
30. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 1998; 58: 1124-1126.
31. Murakami Y, Sekiya T,. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutat Res. 1998; 400: 421-437.
32. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W,. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; 6: 690-693.
33. Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45: 1474-1478.
34. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45: 1470-1473.
35. Murakami Y,. Genetic alterations in human pancreatic cancer. J Hep Bil Pancr Surg. 1997; 4: 283-290.
36. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446: 153-158.
37. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC,. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331: 435-439.
38. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC,. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350: 427-428.
39. Bressac B, Kew M, Wands J, Ozturk M,. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350: 429-431.
40. Murakami Y, Hayashi K, Hirohashi S, Sekiya T,. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991; 51: 5520-5525.
41. Gilbert SF,. Lateral plate mesoderm and endoderm: the specification of liver, pancreas and gallbladder. In:, Gilbert SF, (ed). Developmental biology, 6th edn. Sunderland, MA: Sinauer Associates; 2000. p. 494-498.
42. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011; 54: 2159-2172.
43. Settakorn J, Kaewpila N, Burns GF, Leong AS,. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol. 2005; 58: 1249-1254.
44. Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY,. Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters. World J Gastroenterol. 2008; 14: 3739-3744.
45. Gu MJ, Choi JH,. Clinicopathological significance of E-cadherin, β-catenin and epidermal growth factor receptor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2012; 59: 1241-1244.
46. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol. 2001; 14: 900-905.
47. Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst-Hensch N, Kristiansen G, et al. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol. 2010; 41: 1558-1565.
48. Kong D, Liang J, Li R, Liu S, Wang J, Zhang K, et al. Prognostic significance of snail expression in hilar cholangiocarcinoma. Braz J Med Biol Res. 2012; 45: 617-624.
49. Zhang KJ, Zhang BY, Zhang KP, Tang LM, Liu SS, Zhu DM, et al. Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma. World J Gastroenterol. 2010; 16: 2554-2557.
50. Techasen A, Loilome W, Namwat N, Dokduang H, Jongthawin J, Yongvanit P,. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2012; 13 (Suppl): 115-118.
51. Takamura M, Yamagiwa S, Wakai T, Tamura Y, Kamimura H, Kato T,. Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1and placental growth factor. Int J Oncol. 2010; 36: 245-254.
52. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, et al. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat Genet. 2001; 27: 427-430.
53. Murakami Y,. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 2005; 96: 543-552.
54. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV,. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther. 2002; 1: 293-296.